bluuebunny/crossref_metadata_2025 huggingface dataset:
Assertion-Based Validation using Clustering and Dynamic Refinement of Hardware Checkers
Authors: Sanjaya Sahan , Witharana Hasini , Mishra Prabhat
Published: September 2024

Post-silicon validation is a vital step in System-on-Chip (SoC) design cycle. A major challenge in post-silicon validation is the limited observability of internal signal states using trace buffers. Hardware assertions are promising to improve observability during post-silicon debug. Unfortunately, we cannot synthesize thousands (or millions) of pre-silicon assertions as hardware checkers (coverage monitors) due to hardware overhead constraints. Therefore, we need to select the most profitable assertions based on design constraints. However, the design constraints can also change dynamically during the device lifetime due to changes in use-case scenarios as well as input variations. Therefore, assertion selection needs to dynamically adapt based on changing circumstances. In this article, we propose an assertion-based post-silicon validation framework to address the above challenges. Specifically, this article makes two important contributions. We propose a clustering-based assertion selection technique that can select the most profitable pre-silicon assertions to maximize the fault coverage. We also present a cost-aware dynamic refinement technique that can select beneficial hardware checkers during runtime based on changing design constraints. Experimental evaluation demonstrates that our proposed pre-silicon assertion selection can outperform state-of-the-art assertion ranking methods (Goldmine and HARM). The results also highlight that our proposed post-silicon dynamic refinement can accurately predict area (less than 5% error) and power consumption (less than 3% error) of hardware checkers at runtime. This accurate prediction enables the identification of the most profitable hardware checkers based on design constraints.
Automated anomaly detection for categorical data by repurposing a form filling recommender system
Authors: Belgacem Hichem , Li Xiaochen , Bianculli Domenico , Briand Lionel
Published: September 2024

Data quality is crucial in modern software systems, like data-driven decision support systems. However, data quality is affected by data anomalies, which represent instances that deviate from most of the data. These anomalies affect the reliability and trustworthiness of software systems, and may propagate and cause more issues. Although many anomaly detection approaches have been proposed, they mainly focus on numerical data. Moreover, the few approaches targeting anomaly detection for categorical data do not yield consistent results across datasets.

In this article, we propose a novel anomaly detection approach for categorical data named LAFF-AD (LAFF-based Anomaly Detection), which takes advantage of the learning ability of a state-of-the-art form filling tool (LAFF) to perform value inference on suspicious data. LAFF-AD runs a variant of LAFF that predicts the possible values of a suspicious categorical field in the suspicious instance. LAFF-AD then compares the output of LAFF to the recorded values in the suspicious instance, and uses a heuristic-based strategy to detect categorical data anomalies.

We evaluated LAFF-AD by assessing its effectiveness and efficiency on six datasets. Our experimental results show that LAFF-AD can accurately determine a high range of data anomalies, with recall values between 0.6 and 1 and a precision value of at least 0.808. Furthermore, LAFF-AD is efficient, taking at most 7000s and 735ms to perform training and prediction, respectively.
Scaling Learning-based Policy Optimization for Temporal Logic Tasks by Controller Network Dropout
Authors: Hashemi Navid , Hoxha Bardh , Prokhorov Danil , Fainekos Georgios , Deshmukh Jyotirmoy V.
Published: September 2024

This article introduces a model-based approach for training feedback controllers for an autonomous agent operating in a highly non-linear (albeit deterministic) environment. We desire the trained policy to ensure that the agent satisfies specific task objectives and safety constraints, both expressed in Discrete-Time Signal Temporal Logic (DT-STL). One advantage for reformulation of a task via formal frameworks, like DT-STL, is that it permits quantitative satisfaction semantics. In other words, given a trajectory and a DT-STL formula, we can compute the
robustness
, which can be interpreted as an approximate signed distance between the trajectory and the set of trajectories satisfying the formula. We utilize feedback control, and we assume a feed forward neural network for learning the feedback controller. We show how this learning problem is similar to training recurrent neural networks (RNNs), where the number of recurrent units is proportional to the temporal horizon of the agent’s task objectives. This poses a challenge: RNNs are susceptible to vanishing and exploding gradients, and naïve gradient descent-based strategies to solve long-horizon task objectives thus suffer from the same problems. To address this challenge, we introduce a novel gradient approximation algorithm based on the idea of dropout or gradient sampling. One of the main contributions is the notion of
controller network dropout
, where we approximate the NN controller in several timesteps in the task horizon by the control input obtained using the controller in a previous training step. We show that our control synthesis methodology can be quite helpful for stochastic gradient descent to converge with less numerical issues, enabling scalable back-propagation over longer time horizons and trajectories over higher-dimensional state spaces. We demonstrate the efficacy of our approach on various motion planning applications requiring complex spatio-temporal and sequential tasks ranging over thousands of timesteps.
Antioxidant Properties and Vasorelaxant Mechanism of Aqueous Extract of Ricinodendron heudelotii (Euphorbiaceae)
Authors: Kojom Jacquy Joyce Wanche , Bogning Calvin Zangueu , Lappa Edwige Laure , Sonfack Christelle Stéphanie , Kuinze Augustine Nkojap , Etamé-Loé Gisèle , Dongmo Alain Bertrand
Published: September 2024

Ricinodendron heudelotii is a plant of the Euphorbiaceae family, used in traditional medicine to treat numerous diseases, including high blood pressure. The aim of this study is to evaluate the antioxidant and vasorelaxant effects of the aqueous extract of the stem bark of R. heudelotii.

The pharmacological studies were carried out using the aqueous extract obtained by infusion. The antioxidant capacity of R. heudelotii was assessed by in vitro tests with DPPH (2,2‐diphenyl‐1‐picryl‐hydrazyl), ABTS (2,2 ′‐azino‐bis (3‐ethylbenz‐thiazoline‐6‐sulfonic acid), iron‐reducing capacity (FRAP), and inhibition of nitric oxide (NO) release. In vitro studies, the aortic rings obtained from adult Wistar albino rats of both sexes were used to determine the vasorelaxant effects of the extract of R. heudelotii on the NO and prostacyclin (PGI2) pathways as well as its involvement on various potassium channels were determined on intact or naked fragments of rat aorta precontracted with phenylephrine (10-6 M) or KCl (60 mM).

The aqueous extract of R. heudelotii exhibited a remarkable DPPH (EC50: 1.68 μg/mL) and ABTS (EC50: 106.30 μg/mL) and nitric oxide (53.71% inhibition at 1000 μg/mL) radical scavenging activities as well as reducing power (absorbance of 1.56 at 1000 μg/mL). The nitric oxide inhibitor, NG‐nitro‐L‐arginine methyl ester (L‐NAME), and prostacyclin inhibitor, indomethacin, significantly attenuated the vasodilatory effect of R. heudelotii. Tetraethylammonium could not inhibit the vasodilatory effect of the extract, unlike glibenclamide and barium chloride.

Ricinodendron heudelotii extract possesses antioxidant properties and vasorelaxing effect linked to endothelium‐related factors, and this relaxation was partially mediated mainly through the inhibition of Kir and KATP channels.
Supplementary Data from Integrative Multiomics Analyses Identify Molecular Subtypes of Head and Neck Squamous Cell Carcinoma with Distinct Therapeutic Vulnerabilities
Authors: Diao Pengfei , Dai Yibin , Wang An , Bu Xiaoxuan , Wang Ziyu , Li Jin , Wu Yaping , Jiang Hongbing , Wang Yanling , Cheng Jie
Published: September 2024

Supplementary Materials and Methods
Supplementary Figure S4 from Arginine Methylation of DDX3 by PRMT1 Mediates Mitochondrial Homeostasis to Promote Breast Cancer Metastasis
Authors: Hsu Wen-Jing , Chiang Ming-Chen , Chao Yi-Chun , Chang Yu-Chu , Hsu Ming-Chien , Chung Chu-Hung , Tsai I-Lin , Chu Cheng-Ying , Wu Han-Chung , Yang Ching-Chieh , Lee Chi-Ching , Lin Cheng-Wei
Published: September 2024

PRMT1 and DDX3 are associated with poor prognosis.
Supplementary Figure S2 from Arginine Methylation of DDX3 by PRMT1 Mediates Mitochondrial Homeostasis to Promote Breast Cancer Metastasis
Authors: Hsu Wen-Jing , Chiang Ming-Chen , Chao Yi-Chun , Chang Yu-Chu , Hsu Ming-Chien , Chung Chu-Hung , Tsai I-Lin , Chu Cheng-Ying , Wu Han-Chung , Yang Ching-Chieh , Lee Chi-Ching , Lin Cheng-Wei
Published: September 2024

PRMT1 expression is upregulated in metastatic breast cancer and associates with DDX3.
Suppl video 3 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy
Authors: Yam Andrew O. , Bailey Jacqueline , Lin Francis , Jakovija Arnolda , Youlten Scott E. , Counoupas Claudio , Gunzer Matthias , Bald Tobias , Woodruff Trent M. , Triccas James A. , Goldstein Leonard D. , Gallego-Ortega David , Grey Shane T. , Chtanova Tatyana
Published: September 2024

Neutrophils engage in multiple interactions with LLC tumor cells following microbial bioparticle treatment.
Suppl video 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy
Authors: Yam Andrew O. , Bailey Jacqueline , Lin Francis , Jakovija Arnolda , Youlten Scott E. , Counoupas Claudio , Gunzer Matthias , Bald Tobias , Woodruff Trent M. , Triccas James A. , Goldstein Leonard D. , Gallego-Ortega David , Grey Shane T. , Chtanova Tatyana
Published: September 2024

Neutrophil migration before and after microbial bioparticle treatment.
Supplementary Data from G-quadruplex structures are key modulators of somatic structural variants in cancers
Authors: Zhang Rongxin , Shu Huiling , Wang Yuqi , Tao Tiantong , Tu Jing , Wang Cheng , Mergny Jean-Louis , Sun Xiao
Published: September 2024

Supplementary Figures and Supplementary Methods
Table S4. from Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer
Authors: Malik Navdeep , Kim Young-Im , Yan Hualong , Tseng Yu-Chou , du Bois Wendy , Ayaz Gamze , Tran Andy D. , Vera Ramírez Laura , Yang Howard H. , Michalowski Aleksandra M. , Kruhlak Michael , Lee Maxwell , Hunter Kent W. , Huang Jing
Published: September 2024

This is supplementary Table 4.
Table S3 from Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer
Authors: Malik Navdeep , Kim Young-Im , Yan Hualong , Tseng Yu-Chou , du Bois Wendy , Ayaz Gamze , Tran Andy D. , Vera Ramírez Laura , Yang Howard H. , Michalowski Aleksandra M. , Kruhlak Michael , Lee Maxwell , Hunter Kent W. , Huang Jing
Published: September 2024

This is supplementary Table 3.
TableS2 from Enhancer co-amplification and hijacking promote oncogene expression in liposarcoma
Authors: Liu Tingting , Wang Juan , Yang Hongbo , Jin Qiushi , Wang Xiaotao , Fu Yihao , Luan Yu , Wang Qixuan , Youngblood Mark W. , Lu Xinyan , Casadei Lucia , Pollock Raphael , Yue Feng
Published: September 2024

H3K27Ac ChIP-seq Patient Sample Statistics
TableS1 from Enhancer co-amplification and hijacking promote oncogene expression in liposarcoma
Authors: Liu Tingting , Wang Juan , Yang Hongbo , Jin Qiushi , Wang Xiaotao , Fu Yihao , Luan Yu , Wang Qixuan , Youngblood Mark W. , Lu Xinyan , Casadei Lucia , Pollock Raphael , Yue Feng
Published: September 2024

Patient Sample Information
Supplementary Table S4 from RBM10 loss promotes EGFR-driven lung cancer and confers sensitivity to spliceosome inhibition
Authors: Bao Yufang , Zhang Sirui , Zhang Xiaoyu , Pan Yunjian , Yan Yueren , Wang Ning , Ren Yunpeng , Zuo Ji , Zong Wei-Xing , Wang Zefeng , Wang Yongbo
Published: September 2024

Supplementary Table S4
Supplementary Table S2 from RBM10 loss promotes EGFR-driven lung cancer and confers sensitivity to spliceosome inhibition
Authors: Bao Yufang , Zhang Sirui , Zhang Xiaoyu , Pan Yunjian , Yan Yueren , Wang Ning , Ren Yunpeng , Zuo Ji , Zong Wei-Xing , Wang Zefeng , Wang Yongbo
Published: September 2024

Supplementary Table S2
Figure S1 from DAB2IP is a bifunctional tumor suppressor that regulates wildtype RAS and inflammatory cascades in KRAS mutant colon cancer
Authors: Miller Abigail L. , Perurena Naiara , Gardner Alycia , Hinoue Toshinori , Loi Patrick , Laird Peter W. , Cichowski Karen
Published: September 2024

An immunoblot showing anti-apoptotic NF-kB target genes in shCNT and shDAB2IP HCT116 cells.
Supplementary Data from Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance
Authors: Zhuang Junlong , Shen Lan , Li Meiqian , Sun Jingya , Hao Jiange , Li Jiaxuan , Zhu Zhen , Ge Shuning , Zhang Dianzheng , Guo Hongqian , Huang Ruimin , Yan Jun
Published: September 2024

Supplementary Data
Supplementary Tables from NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer
Authors: Xie Ruihui , Cheng Liang , Huang Ming , Huang Lin , Chen Ziyue , Zhang Qiang , Li Hong , Lu Junlin , Wang Hongjin , Zhou Qianghua , Huang Jian , Chen Xu , Lin Tianxin
Published: September 2024

Supplementary Tables
Supplementary Data from The m6A reader YTHDF2 promotes bladder cancer progression by suppressing RIG-I-mediated immune response
Authors: Zhang Lei , Li Yuqing , Zhou Lingli , Zhou Houhong , Ye Liefu , Ou Tong , Hong Huaishan , Zheng Shiwen , Zhou Ziyu , Wu Kang , Yan Zeqin , Thiery Jean Paul. , Cui Jun , Wu Song
Published: September 2024

Supplementary table ST3
Supplementary Table from Terminally exhausted CD8+ T cells resistant to PD-1 blockade promote generation and maintenance of aggressive cancer stem cells
Authors: Chakravarti Mohona , Dhar Sukanya , Bera Saurav , Sinha Abhipsa , Roy Kamalika , Sarkar Anirban , Dasgupta Shayani , Bhuniya Avishek , Saha Akata , Das Juhina , Banerjee Saptak , Vernekar Manisha , Pal Chiranjib , Alam Neyaz , Datta Dipak , Baral Rathindranath , Bose Anamika
Published: September 2024

Contains supplementary table ST1, ST2 and ST3.
Supplementary Figures from Extrachromosomal Amplification of Human Papillomavirus Episomes is a Mechanism of Cervical Carcinogenesis
Authors: Rossi Nicole M. , Dai Jieqiong , Xie Yi , Wangsa Darawalee , Heselmeyer-Haddad Kerstin , Lou Hong , Boland Joseph F. , Yeager Meredith , Orozco Roberto , Alvirez Freites Enrique , Mirabello Lisa , Gharzouzi Eduardo , Dean Michael
Published: September 2024

Supplementary figures
Supplementary Table 3 from Comprehensive DNA methylation analysis indicates that pancreatic intraepithelial neoplasia lesions are acinar-derived and epigenetically primed for carcinogenesis
Authors: Lo Emily K. W. , Mears Brian M. , Maurer H. Carlo , Idrizi Adrian , Hansen Kasper D. , Thompson Elizabeth D. , Hruban Ralph H. , Olive Kenneth P. , Feinberg Andrew P.
Published: September 2024

Motif analysis
Table S3 from Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma
Authors: Tran Gia-Buu , Ding Jane , Ye Bingwei , Liu Mengling , Yu Yajie , Zha Yunhong , Dong Zheng , Liu Kebin , Sudarshan Sunil , Ding Han-Fei
Published: September 2024

GO analysis of genes down-regulated by simvastatin
Supplementary Table S1 from Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma
Authors: Tran Gia-Buu , Ding Jane , Ye Bingwei , Liu Mengling , Yu Yajie , Zha Yunhong , Dong Zheng , Liu Kebin , Sudarshan Sunil , Ding Han-Fei
Published: September 2024

qRT-PCR primers
Figure S5 from Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression
Authors: DeBlasi Janine M. , Falzone Aimee , Caldwell Samantha , Prieto-Farigua Nicolas , Prigge Justin R. , Schmidt Edward E. , Chio Iok In Christine , Karreth Florian A. , DeNicola Gina M.
Published: September 2024

Supplementary Fig. S5 shows lung tumor analysis data in the KrasG12D/+; p53fl/fl model with single copy Nrf2 deletion.
Supplementary Fig 3 from Ubiquitin ligases Siah1a/2 control alveolar macrophage functions to limit carcinogen-induced lung adenocarcinoma
Authors: Scortegagna Marzia , Du Yuanning , Bradley Linda M. , Wang Kun , Molinolo Alfredo , Ruppin Eytan , Murad Rabi , Ronai Ze'ev A.
Published: September 2024

Sup Fig 3
Supplementary Table S3 from Deficiency of the Polycomb protein RYBP and TET methylcytosine oxidases promotes extensive CpG island hypermethylation and malignant transformation
Authors: Cui Wei , Huang Zhijun , Jin Seung-Gi , Johnson Jennifer , Lau Kin H. , Hostetter Galen , Pfeifer Gerd P.
Published: September 2024

ChIP-seq peaks
Supplementary Table S1 from Deficiency of the Polycomb protein RYBP and TET methylcytosine oxidases promotes extensive CpG island hypermethylation and malignant transformation
Authors: Cui Wei , Huang Zhijun , Jin Seung-Gi , Johnson Jennifer , Lau Kin H. , Hostetter Galen , Pfeifer Gerd P.
Published: September 2024

List of DNA oligonucleotides and antibodies
Supplementary Table S7 from The EstroGene database reveals diverse temporal, context-dependent, and bidirectional estrogen receptor regulomes in breast cancer
Authors: Li Zheqi , Li Tianqin , Yates Megan E. , Wu Yang , Ferber Amanda , Chen Lyuqin , Brown Daniel D. , Carroll Jason S. , Sikora Matthew J. , Tseng George C. , Oesterreich Steffi , Lee Adrian V.
Published: September 2024

ChIP-seq data processing QC parameters
Supplementary Table 1. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Authors: Lundberg Arian , Zhang Meng , Aggarwal Rahul , Li Haolong , Zhang Li , Foye Adam , Sjöström Martin , Chou Jonathan , Chang Kevin , Moreno-Rodriguez Thaidy , Shrestha Raunak , Baskin Avi , Zhu Xiaolin , Weinstein Alana S. , Younger Noah , Alumkal Joshi J. , Beer Tomasz M. , Chi Kim N. , Evans Christopher P. , Gleave Martin , Lara Primo N. , Reiter Rob E. , Rettig Matthew B. , Witte Owen N. , Wyatt Alexander W. , Feng Felix Y. , Small Eric J. , Quigley David A.
Published: September 2024

Clinical characteristics of samples in WCDT cohort
Supplementary Data from Temozolomide sensitizes ARID1A-mutated cancers to PARP inhibitors
Authors: Yu Zheng-Cheng , Li Tianhe , Tully Ellen , Huang Peng , Chen Chih-Ning , Oberdoerffer Philipp , Gaillard Stephanie , Shih Ie-Ming , Wang Tian-Li
Published: September 2024

Supplementary Figures
Supplementary Video 3 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis
Authors: Mukherjee Debarati , Previs Rebecca A. , Haines Corinne , Al Abo Muthana , Juras Patrick K. , Strickland Kyle C. , Chakraborty Binita , Artham Sandeep , Whitaker Regina S. , Hebert Katherine , Fontenot Jake , Patierno Steven R. , Freedman Jennifer A. , Lau Frank H. , Burow Matthew E. , Chang Ching-Yi , McDonnell Donald P.
Published: September 2024

Supplementary Video 3
Supplementary Video 2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis
Authors: Mukherjee Debarati , Previs Rebecca A. , Haines Corinne , Al Abo Muthana , Juras Patrick K. , Strickland Kyle C. , Chakraborty Binita , Artham Sandeep , Whitaker Regina S. , Hebert Katherine , Fontenot Jake , Patierno Steven R. , Freedman Jennifer A. , Lau Frank H. , Burow Matthew E. , Chang Ching-Yi , McDonnell Donald P.
Published: September 2024

Supplementary Video 2
Supplementary Data from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
Authors: Dressel Nicole , Natusch Loreen , Munz Clara M. , Costas Ramon Santiago , Morcos Mina N.F. , Loff Anja , Hiller Björn , Haase Christa , Schulze Livia , Müller Patrick , Lesche Mathias , Dahl Andreas , Luksch Hella , Roesen-Wolff Angela , Roers Axel , Behrendt Rayk , Gerbaulet Alexander
Published: September 2024

Supplementary Figures S1-8 and corresponding figure legends
Figure S3 from Crosstalk between myeloid and B cells shapes the distinct microenvironments of primary and secondary liver cancer
Authors: Chen Zhihang , Zhang Guopei , Ren Xiaoxue , Yao Zhijia , Zhou Qian , Ren Xuxin , Chen Shuling , Xu Lixia , Sun Kaiyu , Zeng Qianwen , Kuang Ming , Kuang Dong-Ming , Peng Sui
Published: September 2024

Figure S3
Table S3 from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Authors: Fattori Stéphane , Le Roy Aude , Houacine Jemila , Robert Lucie , Abes Riad , Gorvel Laurent , Granjeaud Samuel , Rouvière Marie-Sarah , Ben Amara Amira , Boucherit Nicolas , Tarpin Carole , Pakradouni Jihane , Charafe-Jauffret Emmanuelle , Houvenaeghel Gilles , Lambaudie Eric , Bertucci Francois , Rochigneux Philippe , Gonçalves Anthony , Foussat Arnaud , Chrétien Anne-Sophie , Olive Daniel
Published: September 2024

cDC_monocyte_macrophage subpopulations gene features, related to Figure 1
Table S1 from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Authors: Fattori Stéphane , Le Roy Aude , Houacine Jemila , Robert Lucie , Abes Riad , Gorvel Laurent , Granjeaud Samuel , Rouvière Marie-Sarah , Ben Amara Amira , Boucherit Nicolas , Tarpin Carole , Pakradouni Jihane , Charafe-Jauffret Emmanuelle , Houvenaeghel Gilles , Lambaudie Eric , Bertucci Francois , Rochigneux Philippe , Gonçalves Anthony , Foussat Arnaud , Chrétien Anne-Sophie , Olive Daniel
Published: September 2024

Clinical characteristics of patients with breast cancer
File_S1 from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Authors: Fattori Stéphane , Le Roy Aude , Houacine Jemila , Robert Lucie , Abes Riad , Gorvel Laurent , Granjeaud Samuel , Rouvière Marie-Sarah , Ben Amara Amira , Boucherit Nicolas , Tarpin Carole , Pakradouni Jihane , Charafe-Jauffret Emmanuelle , Houvenaeghel Gilles , Lambaudie Eric , Bertucci Francois , Rochigneux Philippe , Gonçalves Anthony , Foussat Arnaud , Chrétien Anne-Sophie , Olive Daniel
Published: September 2024

BGA R script
Supplementary Materials and Methods from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers
Authors: Navarro-Yepes Juliana , Kettner Nicole M. , Rao Xiayu , Bishop Cassandra Santaella. , Bui Tuyen N. , Wingate Hannah F. , Singareeka Raghavendra Akshara , Wang Yan , Wang Jing , Sahin Aysegul A. , Meric-Bernstam Funda , Hunt Kelly K. , Damodaran Senthil , Tripathy Debu , Keyomarsi Khandan
Published: September 2024

This file contains all the supplementary materials and methods referred to in the text.
Supplementary Figure 2 from Galectin-1 mediates chronic STING activation in tumors to promote metastasis through MDSC recruitment
Authors: Nambiar Dhanya K. , Viswanathan Vignesh , Cao Hongbin , Zhang Weiruo , Guan Li , Chamoli Manish , Holmes Brittany , Kong Christina , Hildebrand Rachel , Koong Amanda Jeanette. , von Eyben Rie , Plevritis Sylvia , Li Lingyin , Giaccia Amato , Engleman Edgar , Le Quynh-Thu
Published: September 2024

A. Representative gating strategy for quantification of PMN-MDSCs, M-MDSCs, Ly6C+Mo-MØs, Alveolar macrophages (AMs), Interstitial macrophages (IMs) and myeloid DCs in the lungs of tumor-bearing mice. B. Quantification of PMN-MDSCs (CD11b+Ly6Clo/intLy6G+) in the lungs of MOC2 WT- or KO-Gal1 tumor-bearing mice at matched tumor volumes and of naïve mice. C. Quantitation of CD4+ and CD8+ T cells in MOC2 WT/KO-Gal1 tumor-bearing mice lungs at matched tumor volumes. D. Quantitation of CD8+ T cells in the blood after treatment with either isotype control IgG or anti-mouse CD8a antibody (clone 2.43, BioXCell, 400 μg i.p. twice weekly) in mice bearing MOC2 WT- or KO-Gal1 tumors. E. Quantitation of PMN-MDSCs in the lungs after treatment with either isotype control IgG or anti-mouse CD8a antibody i.p. twice weekly in mice bearing MOC2 WT- or KO-Gal1 tumors. Each dot represents one mouse, and the bar denotes the mean. Student’s t-test (two-tailed) was used to compare the two groups. One-way ANOVA with Tukey’s adjustment was used for comparing multiple treatments to each other. Data are shown as mean+/-SD.
Supplementary Figures from Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma
Authors: Ito Ichiaki , Yousef Abdelrahman M.G. , Chowdhury Saikat , Dickson Princess N. , Naini Zahra Alavi. , White Michael G. , Fleten Karianne Giller. , Flatmark Kjersti , Fournier Keith F. , Fowlkes Natalie W. , Shen John Paul.
Published: September 2024

Figure S1-S8
Supplementary methods from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Authors: Wu Hong , Leng Xuefeng , Liu Qianshi , Mao Tianqin , Jiang Tao , Liu Yiqiang , Li Feifei , Cao Chenhui , Fan Jun , Chen Liang , Chen Yaqi , Yao Quan , Lu Shun , Liang Renchuan , Hu Lanlin , Liu Mingxin , Wan Yejian , Li Zhaoshen , Peng Jun , Luo Qiyu , Zhou Hang , Yin Jun , Xu Ke , Lan Mei , Peng Xinhao , Lan Haitao , Li Gang , Han Yongtao , Zhang Xia , Xiao Zhi-Xiong Jim. , Lang Jinyi , Wang Guihua , Xu Chuan
Published: September 2024

Supplementary methods
Supplementary Table S1 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Authors: Hermida-Prado Francisco , Xie Yingtian , Sherman Shira , Nagy Zsuzsanna , Russo Douglas , Akhshi Tara , Chu Zhengtao , Feit Avery , Campisi Marco , Chen Minyue , Nardone Agostina , Guarducci Cristina , Lim Klothilda , Font-Tello Alba , Lee Irene , García-Pedrero Juana , Canadas Israel , Agudo Judith , Huang Ying , Sella Tal , Jin Qingchun , Tayob Nabihah , Mittendorf Elizabeth A. , Tolaney Sara M. , Qiu Xintao , Long Henry , Symmans William F. , Lin Jia-Ren , Santagata Sandro , Bedrosian Isabelle , Yardley Denise A. , Mayer Ingrid A. , Richardson Edward T. , Oliveira Giacomo , Wu Catherine J. , Schuster Eugene F. , Dowsett Mitch , Welm Alana L. , Barbie David , Metzger Otto , Jeselsohn Rinath
Published: September 2024

Table S1
Data from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Authors: Los-de Vries G. Tjitske , Stathi Phylicia , Rutkens Ryanne , Hijmering Nathalie J. , Luijks Jeroen A.C.W. , Groenen Patricia J.T.A. , de Jong Daphne , Ylstra Bauke , Roemer Margaretha G.M.
Published: September 2024

Abstract
Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary–relapse LBCL-IP sample pairs and performed next-generation sequencing for copy number, mutation, translocation and immunoglobulin clonality analysis. All LBCL-IP sample pairs were clonally related, and both tumors developed from a common progenitor cell (CPC) with MYD88 and TBL1XR1 mutations and/or BCL6 translocations in 30/33 cases, indicating that these are early genetic events. This was succeeded by intermediate genetic events including shared, as well as unique alterations in targets of aberrant somatic hypermutation (aSHM), CD79B mutations and 9p21.3/CDKN2A loss. Genetic alterations in genes involved in immune escape (HLA, CD274/PDL1LG2) were predominantly unique in primary and relapse samples and thus considered late genetic events. Together, this study indicates that primary and relapsed LBCL-IP follow an early parallel evolutionary pattern where the CPC contains genetic alterations that support prolonged survival/proliferation and retention in a memory B-cell state, followed by germinal center re-entry, aSHM and immune escape.
Data from SENP1 decreases RNF168 phase separation to promote DNA damage repair and drug resistance in colon cancer
Authors: Wei Min , Huang Xinping , Liao Liming , Tian Yonglu , Zheng Xiaofeng
Published: September 2024

Abstract
The DNA damage response (DDR) is essential for the maintenance of genomic stability. Protein posttranslational modifications play pivotal roles in regulating the DDR process. Here, we found that SUMOylated RNF168 undergoes liquid-liquid phase separation (LLPS), which restricts the recruitment of RNF168 to DNA damage sites, reduces RNF168-catalyzed H2A ubiquitination, restrains 53BP1 in nuclear condensates, and ultimately impairs non-homologous DNA end joining (NHEJ) repair efficiency. SENP1 was identified as a specific deSUMOylase of RNF168, and it was highly expressed in colorectal adenocarcinoma. In response to DNA damage, SENP1 decreased RNF168 SUMOylation and prevented RNF168 from forming nuclear condensates, thus promoting damage repair efficiency and cancer cell resistance to DNA damaging agents. Moreover, high SENP1 expression correlated with poor prognosis in cancer patients, and SENP1 depletion sensitized cancer cells to chemotherapy. In summary, these findings reveal DDR is suppressed by SUMOylation-induced LLPS of RNF168 and suggest that SENP1 is a potential target for cancer therapy.
Data from Oncogenic ASPM is a regulatory hub of developmental and stemness signaling in cancers
Authors: Tsai Kelvin K. , Bae Byoung-Il , Hsu Chung-Chi , Cheng Li-Hsin , Shaked Yuval
Published: September 2024

Abstract
Despite recent advances in molecularly targeted therapies and immunotherapies, the effective treatment of advanced-stage cancers remains a largely unmet clinical need. Identifying driver mechanisms of cancer aggressiveness can lay the groundwork for the development of breakthrough therapeutic strategies. Assembly factor for spindle microtubules (ASPM) was initially identified as a centrosomal protein that regulates neurogenesis and brain size. Mounting evidence has demonstrated the pleiotropic roles of ASPM in mitosis, cell cycle progression, and DNA double-strand breaks (DSB) repair. Recently, the exon-18-preserved isoform 1 of ASPM has emerged as a critical regulator of cancer stemness and aggressiveness in various malignant tumor types. Here, we describe the domain compositions of ASPM and its transcript variants and overview their expression patterns and prognostic significance in cancers. A summary is provided of recent progress in the molecular elucidation of ASPM as a regulatory hub of development- and stemness-associated signaling pathways, such as the Wnt, Hedgehog, and Notch pathways, and of DNA DSB repair in cancer cells. The review emphasizes the potential utility of ASPM as a cancer-agnostic and pathway-informed prognostic biomarker and therapeutic target.
Data from Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer
Authors: Marin Arnaldo , Mamun Abdullah Al , Patel Hima , Akamatsu Hiroaki , Ye Dan , Sudhan Dhivya R. , Eli Lisa , Marcelain Katherine , Brown Benjamin P. , Meiler Jens , Arteaga Carlos L. , Hanker Ariella B.
Published: September 2024

Abstract
HER2 mutations drive the growth of a subset of breast cancers and are targeted with HER2 tyrosine kinase inhibitors (TKIs) such as neratinib. However, acquired resistance is common and limits the durability of clinical responses. Most HER2-mutant breast cancers progressing on neratinib-based therapy acquire secondary mutations in HER2. It is unknown whether these secondary HER2 mutations, other than the HER2T798I gatekeeper mutation, are causal to neratinib resistance. Herein, we show that secondary acquired HER2T862A and HER2L755S mutations promote resistance to HER2 TKIs via enhanced HER2 activation and impaired neratinib binding. While cells expressing each acquired HER2 mutation alone were sensitive to neratinib, expression of acquired double mutations enhanced HER2 signaling and reduced neratinib sensitivity. Computational structural modeling suggested that secondary HER2 mutations stabilize the HER2 active state and reduce neratinib binding affinity. Cells expressing double HER2 mutations exhibited resistance to most HER2 TKIs but retained sensitivity to mobocertinib and poziotinib. Double-mutant cells showed enhanced MEK/ERK signaling, which was blocked by combined inhibition of HER2 and MEK. Together, these findings reveal the driver function of secondary HER2 mutations in resistance to HER2 inhibition and provide a potential treatment strategy to overcome acquired resistance to HER2 TKIs in HER2-mutant breast cancer.
Data from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Authors: Wu Hong , Leng Xuefeng , Liu Qianshi , Mao Tianqin , Jiang Tao , Liu Yiqiang , Li Feifei , Cao Chenhui , Fan Jun , Chen Liang , Chen Yaqi , Yao Quan , Lu Shun , Liang Renchuan , Hu Lanlin , Liu Mingxin , Wan Yejian , Li Zhaoshen , Peng Jun , Luo Qiyu , Zhou Hang , Yin Jun , Xu Ke , Lan Mei , Peng Xinhao , Lan Haitao , Li Gang , Han Yongtao , Zhang Xia , Xiao Zhi-Xiong Jim. , Lang Jinyi , Wang Guihua , Xu Chuan
Published: September 2024

Abstract
Neoadjuvant chemoimmunotherapy (NACI) has shown promise in the treatment of resectable esophageal squamous cell carcinoma (ESCC). The microbiomes of patients can impact therapy response, and previous studies have demonstrated that intestinal microbiota influences cancer immunotherapy by activating gut immunity. Here, we investigated the effects of intratumoral microbiota on the response of ESCC patients to NACI. Intra-tumoral microbiota signatures of β-diversity were disparate and predicted the treatment efficiency of NACI. The enrichment of Streptococcus positively correlated with GrzB+ and CD8+ T cell infiltration in tumor tissues. The abundance of Streptococcus could predict prolonged disease-free survival in ESCC. Single-cell RNA sequencing (scRNA-seq) demonstrated that responders displayed a higher proportion of CD8+ effector memory T cells but a lower proportion of CD4+ Treg cells. Mice that underwent fecal microbial transplantation (FMT) or intestinal colonization with Streptococcus from responders showed enrichment of Streptococcus in tumor tissues, elevated tumor-infiltrating CD8+ T cells, and a favorable response to anti-PD-1 treatment. Collectively, this study suggests that intratumoral Streptococcus signatures could predict NACI response and sheds light on the potential clinical utility of intratumoral microbiota for cancer immunotherapy. 
Data from Integrative genomic analyses identify lncRNA regulatory networks across pediatric leukemias and solid tumors
Authors: Modi Apexa , Lopez Gonzalo , Conkrite Karina L. , Su Chun , Leung Tsz Ching , Ramanan Sathvik , Manduchi Elisabetta , Johnson Matthew E. , Cheung Daphne , Gadd Samantha , Zhang Jinghui , Smith Malcolm A. , Guidry Auvil Jaime M. , Meshinchi Soheil , Perlman Elizabeth J. , Hunger Stephen P. , Maris John M. , Wells Andrew D. , Grant Struan F.A. , Diskin Sharon J.
Published: September 2024

Abstract
Long non-coding RNAs (lncRNAs) play an important role in gene regulation and contribute to tumorigenesis. While pan-cancer studies of lncRNA expression have been performed for adult malignancies, the lncRNA landscape across pediatric cancers remains largely uncharted. Here, we curated RNA sequencing data for 1,044 pediatric leukemia and extra-cranial solid tumors and integrated paired tumor whole genome sequencing and epigenetic data in relevant cell line models to explore lncRNA expression, regulation, and association with cancer. A total of 2,657 lncRNAs were robustly expressed across six pediatric cancers, including 1,142 exhibiting histotype-elevated expression. DNA copy number alterations contributed to lncRNA dysregulation at a proportion comparable to protein coding genes. Application of a multi-dimensional framework to identify and prioritize lncRNAs impacting gene networks revealed that lncRNAs dysregulated in pediatric cancer are associated with proliferation, metabolism, and DNA damage hallmarks. Analysis of upstream regulation via cell-type specific transcription factors further implicated distinct histotype-elevated and developmental lncRNAs. Integration of these analyses prioritized lncRNAs for experimental validation, and silencing of TBX2-AS1, the top-prioritized neuroblastoma-specific lncRNA, resulted in significant growth inhibition of neuroblastoma cells, confirming the computational predictions. Taken together, these data provide a comprehensive characterization of lncRNA regulation and function in pediatric cancers and pave the way for future mechanistic studies.
Data from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Authors: Singh Rumani , Yu Stacey , Osman Marwa , Inde Zintis , Fraser Cameron , Cleveland Abigail H. , Almanzar Nicole , Lim Chuan Bian , Joshi Gaurav N. , Spetz Johan , Qin Xingping , Toprani Sneh M. , Nagel Zachary , Hocking Matthew C. , Cormack Robert A. , Yock Torunn I. , Miller Jeffrey W. , Yuan Zhi-Min , Gershon Timothy , Sarosiek Kristopher A.
Published: September 2024

Abstract
Although external beam radiation therapy (xRT) is commonly used to treat central nervous system (CNS) tumors in patients of all ages, young children treated with xRT frequently experience life-altering and dose-limiting neurocognitive impairment (NI) while adults do not. The lack of understanding of mechanisms responsible for these differences has impeded the development of neuroprotective treatments. Using a newly developed mouse model of xRT-induced NI, we found that neurocognitive function is impaired by ionizing radiation in a dose- and age-dependent manner, with the youngest animals being most affected. Histological analysis revealed xRT-driven neuronal degeneration and cell death in neurogenic brain regions in young animals but not adults. BH3 profiling showed that neural stem and progenitor cells, neurons, and astrocytes in young mice are highly primed for apoptosis, rendering them hypersensitive to genotoxic damage. Analysis of single cell RNA-seq data revealed that neural cell vulnerability stems from heightened expression of pro-apoptotic genes including BAX, which is associated with developmental and mitogenic signaling by MYC. xRT induced apoptosis in primed neural cells by triggering a p53- and PUMA-initiated, pro-apoptotic feedback loop requiring cleavage of BID and culminating in BAX oligomerization and caspase activation. Notably, loss of BAX protected against apoptosis induced by pro-apoptotic signaling in vitro and prevented xRT-induced apoptosis in neural cells in vivo as well as neurocognitive sequelae. Based on these findings, preventing xRT-induced apoptosis specifically in immature neural cells by blocking BAX, BIM or BID via direct or upstream mechanisms is expected to ameliorate neurocognitive impairment in pediatric CNS tumor patients.
Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
Authors: Wang Zijing , Zhang Nan , Zhang Miao , Jiang Yao , Ng Aik Seng , Bridges Esther , Zhang Wei , Zeng Xin , Luo Qi , Liang Jiabien , Gyorffy Balázs , Hublitz Philip , Liang Zhu , Fischer Roman , Kerr David , Harris Adrian L. , Cai Shijie
Published: September 2024

Abstract
GTP cyclohydrolase (GCH1) is the rate-limiting enzyme for tetrahydrobiopterin (BH4) biosynthesis. The catalysis of BH4 biosynthesis is tightly regulated for physiological neurotransmission, inflammation, and vascular tone. Paradoxically, BH4 has emerged as an oncometabolite regulating tumor growth, but the effects on tumor development remain controversial. Here we found that GCH1 potentiates the growth of triple-negative breast cancer (TNBC) and HER2+ breast cancer and transforms non-tumor breast epithelial cells. Independent of BH4 production, GCH1 protein induced epithelial-to-mesenchymal transition IEMT) by binding to Vim, which was mediated by HSP90. Conversely, GCH1 ablation impaired tumor growth, suppressed Vim in TNBC, and inhibited EGFR/ERK signaling while activating the p53 pathway in estrogen receptor-positive tumor cells. GCH1 deficiency increases tumor cell sensitivity to HSP90 inhibition and endocrine treatments. Additionally, high GCH1 corelated with poor breast cancer survival. Together, this study reveals an enzyme-independent oncogenic role of GCH1, presenting it as a potential target for therapeutic development.
Data from Targeting BCL6 in gastrointestinal stromal tumor promotes p53-mediated apoptosis to enhance the antitumor activity of imatinib
Authors: Zeng Xiangyu , Zhao Fei , Jia Jie , Ma Xianxiong , Jiang Qi , Zhang Ruizhi , Li Chengguo , Wang Tao , Liu Weizhen , Hao Yalan , Tao Kaixiong , Lou Zhenkun , Zhang Peng
Published: September 2024

Abstract
Imatinib mesylate (IM) has revolutionized the treatment of gastrointestinal stromal tumor (GIST). However, most patients inevitably acquire IM resistance. Second- and third-line treatments exhibit modest clinical benefits with a median time to disease progression of 4-6 months, highlighting the urgency for novel therapeutic approaches. Here, we report that the expression of BCL6, a known oncogenic driver and transcriptional repressor, was significantly induced in GIST cells following IM treatment. Elevated BCL6 levels suppressed apoptosis and contributed to IM resistance. Mechanistically, BCL6 recruited SIRT1 to the TP53 promoter to modulate histone acetylation and transcriptionally repress TP53 expression. The reduction in p53 subsequently attenuated cell apoptosis and promoted tolerance of GIST cells to IM. Concordantly, treatment of GIST cells showing high BCL6 expression with a BCL6 inhibitor, BI-3802, conferred IM sensitivity. Furthermore, BI-3802 showed striking synergy with IM in IM-responsive and IM-resistant GIST cells in vitro and in vivo. Thus, these findings reveal a role for BCL6 in IM resistance and suggest that a combination of BCL6 inhibitors and IM could be a potentially effective treatment for GIST.
Table S10 from Using DEPendency of association on the number of Top Hits (DEPTH) as a complementary tool to identify novel colorectal cancer susceptibility loci.
Authors: Lai John , Wong Chi Kuen , Schmidt Daniel F. , Kapuscinski Miroslaw K. , Alpen Karen , Maclnnis Robert J. , Buchanan Daniel D. , Win Aung K. , Figueiredo Jane C. , Chan Andrew T. , Harrison Tabitha A. , Hoffmeister Michael , White Emily , Le Marchand Loic , Pai Rish K. , Peters Ulrike , Hopper John L. , Jenkins Mark A. , Makalic Enes
Published: September 2024

Supplementary Table S10 shows the logistic regression summary statistics for both the CCFR and GECCO datasets.
Supplementary Figure S2 from Prediagnostic prescription antibiotics use and survival in colorectal cancer patients: A Swedish national register-based study
Authors: Lu Sai San Moon , Rutegård Martin , Ahmed Maghfoor , Häggström Christel , Gylfe Åsa , Harlid Sophia , Van Guelpen Bethany
Published: September 2024

Supplementary Figure S2: Model fitness test using Cox-snell residuals for the multivariable model for stage IV colorectal
cancer.
The Cox proportional hazards model was stratified by tumour site (proximal colon, distal colon, rectum,
unspecified), sex (male/female), age at diagnosis (</≥ 50 years), prediagnostic Charlson comorbidity
index (no/any comorbidity), income status (quartiles), and adjusted for age at diagnosis and
prediagnostic Charlson comorbidity index as continuous variables, place of birth, county of residence,
marital status, level of education, family history of colorectal cancer, calendar year at diagnosis, palliative
chemotherapy and surgical therapy as categorical variables, defined as presented in Supplementary
Table S4.
Supplemental Table 6 from Germline mutations in 12 genes and risk of ovarian cancer in three population-based cohorts
Authors: Kotsopoulos Joanne , Hathaway Cassandra A. , Narod Steven A. , Teras Lauren R. , Patel Alpa V. , Hu Chunling , Yadav Siddhartha , Couch Fergus J. , Tworoger Shelley S.
Published: September 2024

Supplemental Table 6: Total number of mutations across 12 cancer predisposing genes among ovarian cancer cases and controls in the NHS, NHSII, and CPSII
Supplemental Figure 2 from Germline mutations in 12 genes and risk of ovarian cancer in three population-based cohorts
Authors: Kotsopoulos Joanne , Hathaway Cassandra A. , Narod Steven A. , Teras Lauren R. , Patel Alpa V. , Hu Chunling , Yadav Siddhartha , Couch Fergus J. , Tworoger Shelley S.
Published: September 2024

Supplemental Figure 2: Kaplan-Meier survival curves for ovarian cancer-specific mortality among cases with Type II tumors (high/unknown grade serous, poorly differentiated, or high grade endometrioid) for A) BRCA1 mutation carriers, B) BRCA2 mutation carriers (solid black lines). Grey lines are women with no mutation in any of the measured high-penetrance genes. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated from Cox Proportional hazard models and were adjusted for age at diagnosis (continuous), year of ovarian cancer diagnosis (continuous), and stage (0, I, II, III, IV, Unknown)
Supplemental Figure 1 from Germline mutations in 12 genes and risk of ovarian cancer in three population-based cohorts
Authors: Kotsopoulos Joanne , Hathaway Cassandra A. , Narod Steven A. , Teras Lauren R. , Patel Alpa V. , Hu Chunling , Yadav Siddhartha , Couch Fergus J. , Tworoger Shelley S.
Published: September 2024

Supplemental Figure 1: Kaplan-Meier survival curves for all-cause mortality among cases with Type II tumors (high/unknown grade serous, poorly differentiated, or high grade endometrioid) for A) BRCA1 mutation carriers, B) BRCA2 mutation carriers (solid black lines). Grey lines are women with no mutation in any of the measured high-penetrance genes. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated from Cox Proportional hazard models and were adjusted for age at diagnosis (continuous), year of ovarian cancer diagnosis (continuous), and stage (0, I, II, III, IV, Unknown)
Supplementary Table 3 from Changes in geographic variation and socioeconomic inequalities in esophageal cancer mortality in China, 1973-2017
Authors: Ran Xianhui , Zheng Rongshou , Zeng Hongmei , Zhang Siwei , Sun Kexin , Han Bingfeng , Wang Shaoming , Chen Ru , Li Li , Wei Wenqiang , He Jie
Published: September 2024

Supplementary Table 3 shows the difference in age-standardized esophageal cancer mortality rates between 90th and 10th percentile counties by province and time period.
Supplementary Methods from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Authors: Tolmeijer Sofie H. , Boerrigter Emmy , Sumiyoshi Takayuki , Kwan Edmond M. , Ng Sarah , Annala Matti , Donnellan Grainne , Herberts Cameron , Benoist Guillemette E. , Hamberg Paul , Somford Diederik M. , van Oort Inge M. , Schalken Jack A. , Mehra Niven , van Erp Nielka P. , Wyatt Alexander W.
Published: September 2024

Additional methodological details
Supplementary Table S4 from SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Authors: Kottschade Lisa A. , Pond Gregory Russell. , Olszanski Anthony J. , Zakharia Yousef , Domingo-Musibay Evidio , Hauke Ralph J. , Curti Brendan D. , Schober Sarah , Milhem Mohammed M. , Block Matthew S. , Hieken Tina , McWilliams Robert R.
Published: September 2024

Outcomes by Subgroups of Primary Site, Adjuvant Radiation, and R0/R1 Resection Margin Status
Supplementary Table S2 from Collagen-anchored interleukin-2 and interleukin-12 safely reprogram the tumor microenvironment in canine soft tissue sarcomas
Authors: Stinson Jordan A. , Sheen Allison , Momin Noor , Hampel Jordan , Bernstein Rebecca , Kamerer Rebecca , Fadl-Alla Bahaa , Samuelson Jonathan , Fink Elizabeth , Fan Timothy M. , Wittrup K. Dane
Published: September 2024

Allometric scaling of IL-2 and IL-12 doses for canine dosing